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A bs tr ac t
Background
Unfractionated heparin is often used as adjunctive therapy with fibrinolysis in pa-
tients with ST-elevation myocardial infarction. We compared a low-molecular-weight 
heparin, enoxaparin, with unfractionated heparin for this purpose.
Methods
We randomly assigned 20,506 patients with ST-elevation myocardial infarction who 
were scheduled to undergo fibrinolysis to receive enoxaparin throughout the index 
hospitalization or weight-based unfractionated heparin for at least 48 hours. The 
primary efficacy end point was death or nonfatal recurrent myocardial infarction 
through 30 days.
Results
The primary end point occurred in 12.0 percent of patients in the unfractionated 
heparin group and 9.9 percent of those in the enoxaparin group (17 percent reduc-
tion in relative risk, P<0.001). Nonfatal reinfarction occurred in 4.5 percent of the 
patients receiving unfractionated heparin and 3.0 percent of those receiving enoxa-
parin (33 percent reduction in relative risk, P<0.001); 7.5 percent of patients given 
unfractionated heparin died, as did 6.9 percent of those given enoxaparin (P = 0.11). 
The composite of death, nonfatal reinfarction, or urgent revascularization occurred 
in 14.5 percent of patients given unfractionated heparin and 11.7 percent of those 
given enoxaparin (P<0.001); major bleeding occurred in 1.4 percent and 2.1 percent, 
respectively (P<0.001). The composite of death, nonfatal reinfarction, or nonfatal 
intracranial hemorrhage (a measure of net clinical benefit) occurred in 12.2 percent 
of patients given unfractionated heparin and 10.1 percent of those given enoxaparin 
(P<0.001).
Conclusions
In patients receiving fibrinolysis for ST-elevation myocardial infarction, treatment 
with enoxaparin throughout the index hospitalization is superior to treatment with 
unfractionated heparin for 48 hours but is associated with an increase in major 
bleeding episodes. These findings should be interpreted in the context of net clini-
cal benefit. (ClinicalTrials.gov number, NCT00077792.)
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Fibrinolysis is the most common method of reperfusion used worldwide for patients with ST-elevation myocardial infarc-
tion. In addition to advocating that a fibrinolytic 
agent be combined with aspirin, contemporary 
guidelines recommend the routine administration 
of unfractionated heparin.1,2 Despite receiving a 
regimen of a fibrinolytic agent, aspirin, and un-
fractionated heparin, a substantial number of pa-
tients die or have another nonfatal myocardial 
infarction within one month after treatment.3-9 
Prolonged intravenous infusions of unfractionated 
heparin have not been shown to prevent reocclu-
sion after angiographically proven successful fi-
brinolysis, leading to the current recommendation 
to limit the duration of infusion to 48 hours.1,2 The 
use of unfractionated heparin requires frequent 
monitoring to adjust the infusion rate to maintain 
a therapeutic range of anticoagulation.10
The low-molecular-weight heparins are poten-
tial replacements for unfractionated heparin.11,12 
As compared with unfractionated heparin, enoxa-
parin (Lovenox, Sanofi-Aventis) provides both a 
reliable level of anticoagulation without the need 
for therapeutic monitoring and relatively greater 
proximal inhibition of the coagulation cascade 
because it results in a ratio of anti–factor Xa to 
anti–factor IIa activity of 3.8:1.10 The Enoxaparin 
and Thrombolysis Reperfusion for Acute Myocar-
dial Infarction Treatment (ExTRACT)–Thromboly-
sis in Myocardial Infarction (TIMI) 25 study was 
designed to compare enoxaparin and unfraction-
ated heparin as adjunctive therapy for fibrinoly-
sis in ST-elevation myocardial infarction.11 Because 
of the advantage offered by the ability to admin-
ister enoxaparin subcutaneously, we tested a strat-
egy in which enoxaparin was administered for the 
duration of the index hospitalization, to decrease 
the risk of reocclusion of the infarct artery. Since 
enoxaparin reportedly increases the risk of bleed-
ing in elderly patients,13 we devised a specific 
dosing regimen for patients 75 years of age or 
older and reduced the dose in patients of any age 
who had a clinically significant impairment in 
renal function.11
Me thods
Patient Population
Between October 24, 2002, and October 1, 2005, 
20,506 patients underwent randomization at 674 
sites in 48 countries (see the Appendix). Eligible 
patients were at least 18 years of age, had at least 
20 minutes of ischemic symptoms while at rest 
within 6 hours before randomization, had ST-seg-
ment elevation of at least 0.1 mV in two limb leads 
or of 0.2 mV in at least two contiguous precordial 
leads or had left bundle-branch block, and were 
scheduled to undergo fibrinolysis with streptoki-
nase, tenecteplase, alteplase, or reteplase.11 Patients 
were ineligible if they had any of the following 
major exclusion criteria: cardiogenic shock, peri-
carditis, symptoms of aortic dissection, contrain-
dications to fibrinolysis, receipt of a low-molecu-
lar-weight heparin within the prior eight hours, 
known renal insufficiency (defined by a serum cre-
atinine level of greater than 220 μmol per liter 
[2.5 mg per deciliter] for men and greater than 
175 μmol per liter [2.0 mg per deciliter] for wom-
en), or a life expectancy of less than 12 months.11
The protocol was approved by the local insti-
tutional review board at participating centers. 
Written informed consent was obtained from 
all patients in the intention-to-treat and safety 
populations, except for six, who provided oral 
informed consent.
Study Protocol
Patients were to receive, at the treating physician’s 
discretion, streptokinase, tenecteplase, alteplase, 
or reteplase according to the manufacturers’ in-
structions for the treatment of ST-elevation myo-
cardial infarction. All patients were to receive 
150 to 325 mg of aspirin in a nonenteric formula-
tion orally or 500 mg intravenously unless they 
had received at least 325 mg of aspirin within the 
prior 24 hours. After the first 24 hours, mainte-
nance therapy with 75 to 325 mg of aspirin once 
daily was to be administered orally for at least 30 
days. Alternative antiplatelet agents such as clo-
pid ogrel could be used in patients with an allergy 
to aspirin, or they could be added to aspirin at the 
investigator’s discretion, as part of the patient’s 
treatment regimen.
Patients were randomly assigned in a 1:1 ratio 
to receive enoxaparin or unfractionated heparin 
with the use of a central, computerized system, 
according to the type of fibrinolytic agent. Study 
medication was to be administered in a double-
blind fashion with the use of a double-dummy 
design between 15 minutes before and 30 minutes 
after the initiation of fibrinolytic therapy and was 
to occur within 30 minutes after randomization.
Unfractionated heparin (or matching placebo) 
was to be administered beginning with an intra-
venous bolus of 60 U per kilogram of body weight 
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(maximum, 4000 U). The intravenous bolus was 
to be omitted for patients who received open-label 
unfractionated heparin (at least 4000 U) within 
three hours before randomization. Within 15 min-
utes after the intravenous bolus, an infusion of 
12 U per kilogram per hour (initial maximum, 
1000 U per hour) was begun. All monitoring of 
anticoagulation to adjust the dose of unfraction-
ated heparin to maintain an activated partial-
thromboplastin time of 1.5 to 2.0 times the con-
trol value was performed in a blinded fashion by 
personnel caring for the patient or in an unblinded 
fashion by a designated medical professional not 
involved in the patient’s care.11 The intravenous 
infusion was to be given for at least 48 hours but 
could be continued for a longer period at the treat-
ing physician’s discretion.
The enoxaparin dosing strategy was adjusted 
according to the patient’s age and renal function. 
For patients younger than 75 years of age, enoxa-
parin (or matching placebo) was to be given as a 
fixed, 30-mg intravenous bolus followed 15 min-
utes later by a subcutaneous injection of 1.0 mg 
per kilogram, with injections administered every 
12 hours. For patients at least 75 years of age, the 
intravenous bolus was eliminated and the subcu-
taneous dose was reduced to 0.75 mg per kilogram 
every 12 hours. For the first two subcutaneous 
injections, a maximum of 100 mg (for patients 
less than 75 years old) or 75 mg (for those at least 
75 years old) was to be administered. To reduce 
the risk of bleeding, the intravenous bolus was to 
be omitted for patients who received open-label 
unfractionated heparin (at least 4000 U) within 
three hours before randomization. For patients 
with an estimated creatinine clearance of less than 
30 ml per minute, the dose was to be modified to 
1.0 mg per kilogram every 24 hours.11 The dou-
ble-blind subcutaneous injections of enoxaparin 
or matching placebo were to continue until hospi-
tal discharge or for a maximum of eight days 
(whichever came first).
Although percutaneous coronary interventions 
could be performed at any time as rescue therapy 
for failed fibrinolysis or urgently, in response to 
an episode of recurrent myocardial ischemia or 
infarction, the protocol recommended the defer-
ral of elective procedures for at least 48 hours after 
randomization. Patients undergoing percutaneous 
coronary interventions were to receive antithrom-
botic support with masked study drug, which 
could be discontinued after uncomplicated pro-
cedures at the discretion of the treating physi-
cian.11 Patients were monitored for clinical end 
points and adverse events during the index hos-
pitalization and through day 30 (ascertained, day 
31 to 38) in person or by telephone.
End Points
The primary efficacy end point was the composite 
of death from any cause or nonfatal recurrent myo-
cardial infarction in the first 30 days after ran-
domization. The main secondary end point was 
the composite of death from any cause, nonfatal 
reinfarction, or recurrent myocardial ischemia lead-
ing to urgent revascularization in the first 30 days. 
An additional secondary end point (net clinical ben-
efit) was the composite of death from any cause, 
nonfatal reinfarction, or nonfatal disabling stroke. 
We included two other prespecified net-clinical-
benefit end points: first, death, nonfatal recurrent 
myocardial infarction, or a nonfatal episode of ma-
jor bleeding; and second, death, nonfatal myocar-
dial infarction, or nonfatal intracranial hemor-
rhage. Bleeding was classified according to the 
TIMI criteria.11 All ischemic and clinically signifi-
cant bleeding events were adjudicated in a blinded 
fashion by an independent clinical-events commit-
tee using prespecified definitions.11
Statistical Analysis
The trial was designed to have a statistical power 
of at least 90 percent to detect a 13 percent rela-
tive risk reduction in the primary end point with 
enoxaparin and used an event-driven approach. We 
estimated that randomization of approximately 
21,000 patients would be required to yield the tar-
get of 2080 events.
All efficacy comparisons were analyzed ac-
cording to the intention-to-treat principle. The 
analysis of the primary efficacy end point in-
cluded all primary efficacy end points known to 
have occurred through 30 days after randomiza-
tion and in the database that was locked on Janu-
ary 27, 2006. We prospectively planned to sum-
marize events occurring after day 30 that were 
identified on the visit at day 30 (range, day 31 to 
38) in a 6-month study report. The chi-square 
test was used to compare the primary and sec-
ondary end points in the two treatment groups. 
A log-rank test was also performed. All safety 
analyses were performed according to the treat-
ment actually received by the patient.
An independent data and safety monitoring 
board monitored efficacy and safety. Prespecified 
interim analyses for efficacy and safety were con-
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ducted after approximately 25 percent, 50 per-
cent, and 75 percent of the total targeted num-
ber of primary end-point events had occurred, 
according to the Lan–DeMets type of O’Brien–
Fleming stopping boundary. The critical two-sid-
ed P value for the final analysis of the primary 
efficacy end point, after correction for interim 
analyses, was 0.043. A P value of less than 0.05 
was the threshold for nominal significance for all 
other end points.
The trial was designed as a collaborative effort 
between members of the steering committee and 
the sponsor, Sanofi-Aventis. The data were col-
lected by a contract research organization (Quin-
tiles). The raw database was provided by the spon-
sor to members of the TIMI Study Group. The 
prespecified and exploratory analyses were car-
ried out independently by the TIMI Study Group 
(whose members wrote this report and take re-
sponsibility for the data) as well as the sponsor.
Table 1. Baseline Characteristics of the Patients.* 
Characteristic
Enoxaparin
(N = 10,256)
Unfractionated Heparin
(N = 10,223)
P 
Value
Age — yr 0.35
Median 59 60 
Interquartile range 51–69 51–69
Age ≥75 yr — no. (%) 1241 (12.1) 1291 (12.6) 0.25
Male sex — no. (%) 7841 (76.5) 7855 (76.8) 0.52
White race — no./total no. (%)† 8935/10,255 (87.1) 8920/10,223 (87.3) 0.79
Weight — kg 0.22
Median 76 76
Interquartile range 68–86 68–85
Hypertension — no./total no. (%) 4505/10,128 (44.5) 4401/10,105 (43.6) 0.18
Hyperlipidemia — no./total no. (%) 1462/7979 (18.3) 1455/7990 (18.2) 0.85
Current smoker — no./total no. (%) 4855/10,254 (47.3) 4837/10,215 (47.4) 0.99
Diabetes mellitus — no./total no. (%) 1545/10,145 (15.2) 1515/10,104 (15.0) 0.64
Prior myocardial infarction — no./total no. (%) 1349/10,214 (13.2) 1310/10,190 (12.9) 0.46
Prior angina pectoris — no./total no. (%) 2864/10,179 (28.1) 2851/10,166 (28.0) 0.88
Prior percutaneous coronary intervention — 
no./total no. (%)
340/10,244 (3.3) 320/10,217 (3.1) 0.45
Anterior myocardial infarction — no./total no. (%) 4439/10,176 (43.6) 4494/10,157 (44.2) 0.37
Long-term treatment with aspirin — no./total no. (%) 1396/10,231 (13.6) 1356/10,205 (13.3) 0.45
Unfractionated heparin within 3 hr before randomization 
— no./total no. (%)
1634/10,255 (15.9) 1608/10,223 (15.7) 0.69
LMWH within 7 days before randomization — 
no./total no. (%)
43 (0.4) 50 (0.5) 0.46
Creatinine clearance — ml/min 0.23
Median 82.3 82.0
Interquartile range 63.6–104.6 63.1–104.2
Killip class — no. (%)
I 9098 (88.8) 9078 (88.8) 0.92
II 1049 (10.2) 1036 (10.1)
III 94 (0.9) 99 (1.0)
IV 6 (0.1) 8 (0.1)
Data missing 9 (0.1) 2 (<0.1)
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R esult s
A total of 20,506 patients underwent randomiza-
tion, of whom 20,479 were included in the inten-
tion-to-treat population; they were well matched 
for baseline characteristics (Table 1). The profile 
of their characteristics was similar to that seen in 
contemporary trials of interventions for ST-eleva-
tion myocardial infarction. The treatment groups 
were well matched with respect to concomitant 
therapy with other guideline-recommended treat-
ments, such as aspirin, beta-blockers, and inhib-
itors of the renin–angiotensin system; the major-
ity of patients received all these treatments.
A fibrinolytic agent was administered to 99.7 
percent of patients, with 79.5 percent receiving a 
fibrin-specific agent and 20.2 percent receiving 
streptokinase (Table 1). The median time from 
the onset of symptoms to the start of fibrinolytic 
therapy was 3.2 hours.
A total of 15.8 percent of patients had received 
open-label unfractionated heparin in the three 
hours preceding randomization, and 0.5 percent 
had received low-molecular-weight heparin in the 
seven days preceding randomization (Table 1). 
Study drug was administered in a blinded fashion 
to 99.2 percent of patients, with 97.1 percent re-
ceiving it within 30 minutes after the start of 
fibrinolytic therapy.
As anticipated by the protocol design, treat-
Table 1. (Continued.)
Characteristic
Enoxaparin
(N = 10,256)
Unfractionated 
Heparin
(N = 10,223)
P 
Value
TIMI risk score — no./total no. (%)‡ 0.84
≤3 6534/10,139 (64.4) 6519/10,137 (64.3)
>3 3605/10,139 (35.6) 3618/10,137 (35.7)
Time from symptom onset to start of fibrinolytic therapy — hr 0.65
Median 3.1 3.2 
Interquartile range 2.2–4.3 2.2–4.3
Fibrinolytic therapy — no. (%) 0.91
Tenecteplase 1976 (19.3) 2010 (19.7)
Alteplase 5605 (54.7) 5570 (54.5)
Reteplase 561 (5.5) 561 (5.5)
Streptokinase 2083 (20.3) 2056 (20.1)
None 31 (0.3) 26 (0.3)
Time from fibrinolytic therapy to study-drug administration — 
no./total no. (%)
0.09
>15 min   27/10,157 (0.3) 41/10,144 (0.4)
0–15 min 1216/10,157 (12.0) 1140/10,144 (11.2)
0–30 min 8604/10,157 (84.7) 8677/10,144 (85.5)
>30 min 310/10,157 (3.1) 286/10,144 (2.8)
Cardiac medications during index hospitalization — no. (%)
Aspirin 9727 (94.8) 9749 (95.4) 0.08
Clopidogrel 2788 (27.2) 2939 (28.7) 0.01
Beta-blockers 8811 (85.9) 8745 (85.5) 0.45
ACE inhibitors or angiotensin-receptor blockers 8208 (80.0) 8109 (79.3) 0.21
Statin 7124 (69.5) 7103 (69.5) 0.98
* LMWH denotes low-molecular-weight heparin, and ACE angiotensin-converting enzyme.
† Race was self-reported.
‡ The TIMI risk score was calculated as described previously11 and was based on the results for 10,139 patients in the 
enoxaparin group and 10,137 patients in the unfractionated heparin group. Higher scores indicate higher risk.
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ment with enoxaparin lasted a median of 7.0 days 
(defined as 24-hour intervals after randomization) 
(interquartile range, 4.5 to 7.5; 90th percentile, 7.5) 
and treatment with unfractionated heparin last-
ed a median of 2.0 days (interquartile range, 2.0 
to 2.2; 90th percentile, 3.2). The median dura-
tion of hospitalization for the study population 
was 10 days (interquartile range, 7 to 17). The 
qualifying infarction was treated with medical 
therapy alone in 74.3 percent of patients, a per-
cutaneous coronary intervention in 23.0 percent 
(as rescue therapy in 2.8 percent and as an urgent 
or elective procedure in 20.2 percent), and coro-
nary-artery bypass surgery in 2.8 percent of pa-
tients.
Efficacy End Points
The primary end point was ascertained at 30 days 
in all but three patients in the intention-to-treat 
population. The rate of the primary efficacy end 
point (death or nonfatal myocardial infarction) 
was 9.9 percent in the enoxaparin group, as com-
pared with 12.0 percent in the unfractionated 
heparin group (17 percent reduction in the rela-
tive risk, P<0.001) (Table 2 and Fig. 1A). The ben-
eficial effect of enoxaparin on the primary end 
point was consistent across key prespecified sub-
groups (Fig. 2). In addition, there was a signifi-
cant treatment benefit of enoxaparin, as compared 
with unfractionated heparin, in patients who un-
derwent percutaneous coronary intervention with-
in 30 days after randomization (23 percent reduc-
tion in relative risk) or who were treated medically 
(16 percent reduction in relative risk, P = 0.33 for 
interaction). The treatment benefits of enoxaparin, 
evident for a number of efficacy outcomes, emerged 
at 48 hours, at which time there was a 33 percent 
reduction in the relative risk of nonfatal myocar-
dial infarction, as compared with treatment with 
unfractionated heparin (P = 0.002) (Table 2).
At 30 days, the mortality rate was 7.5 percent 
in the unfractionated heparin group, as compared 
Table 2. Efficacy Outcomes.*
Outcome
Enoxaparin
(N = 10,256)
Unfractionated
Heparin
(N = 10,223)
Relative Risk 
(95% CI) P Value
number (percent)
Outcome at 48 hr
Death or nonfatal MI 478 (4.7) 531 (5.2) 0.90 (0.80–1.01) 0.08
Death 383 (3.7) 390 (3.8) 0.98 (0.85–1.12) 0.76
Nonfatal MI 95 (0.9) 141 (1.4) 0.67 (0.52–0.87) 0.002
Urgent revascularization 74 (0.7) 96 (0.9) 0.77 (0.57–1.04) 0.09
Death, nonfatal MI, or urgent revascularization 548 (5.3) 622 (6.1) 0.88 (0.79–0.98) 0.02
Outcome at 8 days
Death or nonfatal MI 740 (7.2) 954 (9.3) 0.77 (0.71–0.85) <0.001
Death 559 (5.5) 605 (5.9) 0.92 (0.82–1.03) 0.15
Nonfatal MI 181 (1.8) 349 (3.4) 0.52 (0.43–0.62) <0.001
Urgent revascularization 145 (1.4) 247 (2.4) 0.59 (0.48–0.72) <0.001
Death, nonfatal MI, or urgent revascularization 874 (8.5) 1181 (11.6) 0.74 (0.68–0.80) <0.001
Outcome at 30 days
Primary efficacy end point (death or nonfatal MI) 1017 (9.9) 1223 (12.0) 0.83 (0.77–0.90) <0.001
Death 708 (6.9) 765 (7.5) 0.92 (0.84–1.02) 0.11
Nonfatal MI 309 (3.0) 458 (4.5) 0.67 (0.58–0.77) <0.001
Urgent revascularization 213 (2.1) 286 (2.8) 0.74 (0.62–0.88) <0.001
Death, nonfatal MI, or urgent revascularization 1199 (11.7) 1479 (14.5) 0.81 (0.75–0.87) <0.001
* Nonfatal myocardial infarction (MI) indicates that a patient had a recurrent MI and had not died by the time shown. 
Urgent revascularization denotes episodes of recurrent myocardial ischemia (without infarction) that drove the clinical 
decision to perform coronary revascularization during the same hospitalization.11 CI denotes confidence interval.
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with 6.9 percent in the enoxaparin group (P = 0.11) 
(Table 2). Enoxaparin significantly reduced the 
rate of recurrent nonfatal myocardial infarction 
(3.0 percent, vs. 4.5 percent in the unfractionated 
heparin group; 33 percent reduction in the rela-
tive risk; P<0.001) (Table 2). Episodes of recurrent 
myocardial ischemia leading to urgent revascu-
larization were significantly reduced, from 2.8 
percent in the unfractionated heparin group to 
2.1 percent in the enoxaparin group (P<0.001) 
(Table 2). As compared with unfractionated hepa-
rin, enoxaparin also significantly reduced the in-
cidence of the main secondary end point of death, 
nonfatal myocardial infarction, or urgent revas-
cularization (11.7 percent vs. 14.5 percent, P<0.001) 
(Table 2 and Fig. 1B).
Safety End Points
The rates of TIMI major bleeding (including in-
tracranial hemorrhage) at 30 days were 1.4 per-
cent in the unfractionated heparin group and 2.1 
percent in the enoxaparin group (absolute in-
crease of 0.7 percentage point and 53 percent in-
crease in the relative risk, P<0.001) (Table 3). The 
rates of intracranial hemorrhage were 0.7 percent 
in the unfractionated heparin group and 0.8 per-
cent in the enoxaparin group (P = 0.14). The respec-
tive rates of minor bleeding and the composite of 
major or minor bleeding were 0.8 and 1.5 percent-
age points higher in the enoxaparin group than 
in the group given unfractionated heparin (relative 
risk, 1.41 and 1.47, respectively) (Table 3).
Net Clinical Benefit
The rates of all three prespecified net-clinical-
benefit composite end points were significantly 
lower at 30 days in the enoxaparin group than in 
the unfractionated heparin group (Table 4). Enoxa-
parin had a similar, beneficial effect on these end 
points, which are composites of efficacy and dif-
ferent aspects of safety (nonfatal disabling stroke, 
nonfatal major bleeding, and nonfatal intracra-
nial hemorrhage). The range of reductions in the 
absolute event rates was 1.8 to 2.2 percentage 
points, corresponding to reductions in the rela-
tive risk of 14 to 18 percent (P<0.001 for all com-
parisons).
Discussion
Our results demonstrate that a strategy of admin-
istering enoxaparin throughout the index hospi-
talization is superior to the current strategy of ad-
ministering unfractionated heparin for 48 hours 
as adjunctive antithrombin therapy for patients 
with ST-elevation myocardial infarction who un-
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Figure 1. Cumulative Incidence of the Primary End Point (Panel A) 
and the Secondary End Point (Panel B).
In Panel A, the rate of the primary e d point (death or nonfatal myocardial 
infarction) at 30 days was significantly lower in the enoxaparin group than 
in the unfractionated heparin group (9.9 percent vs. 12.0 percent, P<0.001 
by the log-rank test). The dashed vertical line indicates the comparison at 
day 2 (direct pharmacologic comparison), at which time a trend in favor of 
enoxaparin was seen. In Panel B, the rate of the main secondary end point 
(death, nonfatal myocardial infarction, or urgent revascularization) at 30 
days was significantly lower in the enoxaparin group than in the unfraction-
ated heparin group (11.7 percent vs. 14.5 percent, P<0.001 by the log-rank 
test). The difference was already significant at 48 hours (6.1 percent in the 
unfractionated heparin group vs. 5.3 percent in the enoxaparin group, 
P = 0.02 by the log-rank test). The interval shown is the time (in 24-hour in-
tervals) from randomization to an event or the last follow-up visit. CI de-
notes confidence interval.
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dergo pharmacologic reperfusion with a fibrino-
lytic agent. Although antithrombin agents have 
not been reported to enhance initial clot lysis, 
their use as part of a pharmacologic reperfusion 
regimen is associated with a higher rate of pa-
tency of the infarct artery hours to days after ini-
tial fibrinolytic therapy and a lower rate of recur-
rent myocardial infarction.14-16 After initially 
successful fibrinolysis, reocclusion of the infarct 
artery is associated with a near tripling of mor-
tality.17-19 The risk of reocclusion is related to the 
underlying degree of stenosis and the residual 
thrombus.20-22
Three factors may have contributed to the treat-
ment differences we observed: a superior anti-
thrombotic effect of enoxaparin, a longer duration 
of treatment with enoxaparin, and possibly, a re-
bound increase in thrombotic events after the 
discontinuation of unfractionated heparin, as sug-
gested by the shape of the curves in Figure 1. We 
are unable to determine definitively the relative 
contributions of each of these factors to the re-
sults observed.
The significant 33 percent reduction in the 
relative risk of myocardial reinfarction at 30 days 
with enoxaparin suggests that the antithrombotic 
effect of this agent is superior to that achieved with 
the currently recommended regimen of unfraction-
ated heparin. We also observed a 26 percent re-
duction in the need for urgent revascularization 
at 30 days in the enoxaparin group (Table 2). The 
superior antithrombotic effect of enoxaparin may 
Sex
Male
Female
Age 
<75 yr
≥75 yr
Infarct location
Anterior
Other
Diabetes
No
Yes
Prior MI
No
Yes
Fibrinolytic agent
Streptokinase
Fibrin-specific
Time to treatment
<Median
≥Median
Overall
Subgroup
Reduction
in Risk
18 
16 
20 
6 
11 
23 
17 
21 
17 
20 
13 
18 
23 
12 
17
No. of
Patients
15,696 
4,783
17,947 
2,532 
8,933 
11,400 
17,189 
3,060 
17,745 
2,659 
4,139 
16,283 
9,899 
10,394 
20,479
0.5 1.0
Unfractionated
Heparin Better
Enoxaparin
Better
Relative Risk End Point
10.1 
18.3 
9.9 
26.3 
14.0 
10.2 
11.1 
17.1 
11.1 
17.8 
11.8 
12.0 
11.3 
12.5 
12.0
8.2 
15.4 
7.9 
24.8 
12.5 
7.9 
9.2 
13.6 
9.2 
14.3 
10.2 
9.8 
8.7 
11.0 
9.9
Unfractionated
Heparin Enoxaparin
percent
Figure 2. Relative Risks of and Absolute Event Rates for the Primary End Point at 30 Days in Various Subgroups.
The primary efficacy end point was the composite of death from any cause or nonfatal recurrent myocardial infarc-
tion (MI) in the first 30 days. The overall treatment effect of enoxaparin as compared with unfractionated heparin is 
shown by the diamond (whose left and right edges represent the 95 percent confidence interval) and the dashed 
vertical line. For each subgroup, the square is proportional to the number of patients and represents the point esti-
mate of the treatment effect and the horizontal lines represent the 95 percent confidence intervals. Fibrin-specific 
fibrinolytic agents included alteplase, tenecteplase, and reteplase. Time to treatment indicates the time from the 
onset of symptoms to the administration of study drug (median, 3.2 hours). Although there was some variation in 
the estimate of the treatment effect of enoxaparin on the primary end point across the subgroups shown, all P val-
ues in tests for interaction were nonsignificant.
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be explained, in part, by its greater ratio of anti–
factor Xa to anti–factor IIa activity, since the inhi-
bition of a single molecule of factor Xa inhibits 
the downstream production of many thrombin 
molecules.10,23
The convenience of the subcutaneous route of 
administration was a factor in our decision to 
test a strategy of administering enoxaparin for the 
duration of the index hospitalization. Extended 
treatment with enoxaparin most likely contribut-
ed to a more sustained antithrombotic effect. It 
is notable that the rate of the main secondary end 
point of death, nonfatal myocardial infarction, or 
urgent revascularization was significantly lower 
in the enoxaparin group than in the unfraction-
ated heparin group within 48 hours. Previous work 
failed to show that the infusion of unfraction-
ated heparin for more than 48 hours prevents 
reocclusion of successfully reperfused infarct ar-
teries in patients with ST-elevation myocardial 
infarction.1,2,24 Furthermore, no strategies for 
dealing with the possibility of rebound after the 
discontinuation of unfractionated heparin have 
been rigorously examined, and rebound may oc-
cur after treatment with unfractionated heparin 
regardless of the duration of the infusion.10
There was no significant increase in the rate 
of intracranial hemorrhage with enoxaparin ther-
apy. There was, however, a significant increase 
in episodes of major bleeding. Although com-
parisons across trials are difficult because of the 
possible effect of differences in definitions of 
bleeding, the rates of major bleeding in both treat-
ment groups were lower than those reported in 
a prior meta-analysis (in which the in-hospital rate 
of major bleeding was 3.3 percent with enoxapa-
rin and 2.5 percent with unfractionated heparin).12 
The low rate of use of open-label unfractionated 
Table 3. Safety Outcomes.*
Outcome
Enoxaparin
(N = 10,176)
Unfractionated
Heparin
(N = 10,151)
Relative Risk
(95% CI) P Value
number (percent)
Outcome at 48 hr
Major bleeding (including ICH) 146 (1.4) 101 (1.0) 1.44 (1.12 –1.86) 0.004
ICH 68 (0.7) 56 (0.6) 1.21 (0.85–1.72) 0.29
Minor bleeding 159 (1.6) 122 (1.2) 1.30 (1.03 –1.64) 0.028
Major or minor bleeding 301 (3.0) 219 (2.2) 1.37 (1.15–1.63) <0.001
Outcome at 8 days
Major bleeding (including ICH) 185 (1.8) 124 (1.2) 1.49 (1.19–1.87) <0.001
ICH 81 (0.8) 62 (0.6) 1.30 (0.94–1.81) 0.11
Minor bleeding 236 (2.3) 162 (1.6) 1.45 (1.19–1.77) <0.001
Major or minor bleeding 415 (4.1) 279 (2.7) 1.48 (1.28–1.72) <0.001
Outcome at 30 days
Major bleeding (including ICH) 211 (2.1) 138 (1.4) 1.53 (1.23–1.89) <0.001
ICH 84 (0.8) 66 (0.7) 1.27 (0.92–1.75) 0.14
Minor bleeding 260 (2.6) 184 (1.8) 1.41 (1.17–1.70) <0.001
Major or minor bleeding 464 (4.6) 315 (3.1) 1.47 (1.28–1.69) <0.001
* Safety events were assessed in the treated population. There were 15 patients in the safety population who were treated 
with study drug without undergoing randomization. Bleeding was assessed according to the TIMI criteria. A total of 
37.9 percent of patients in the enoxaparin group and 31.9 percent in the unfractionated heparin group who had a major 
bleeding episode died (P = 0.25). In patients who had a major bleeding episode, the mortality rate at 30 days was 0.8 
percent in the enoxaparin group (80 of 10,176) and 0.4 percent in the unfractionated heparin group (44 of 10,151; 
P = 0.001). Among the 80 deaths in the enoxaparin group, the primary cause was considered to be hemorrhagic in 56 
(70 percent), cardiovascular in 19 (24 percent), noncardiovascular in 4 (5 percent), and unknown in 1 (1 percent). 
Among the 44 deaths in the unfractionated heparin group, the primary cause was considered to be hemorrhagic in 34 
(77 percent), cardiovascular in 9 (20 percent), and noncardiovascular in 1 (2 percent). In patients who had a nonfatal 
intracranial hemorrhage, 46.2 percent (12 of 26) in the enoxaparin group and 62.1 percent (18 of 29) in the unfraction-
ated heparin group had a significant permanent neurologic disability (P = 0.24).
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heparin before randomization, the use of conser-
vative dosing strategies, and avoidance of double 
anticoagulation through the use of masked study 
drug to support percutaneous coronary interven-
tions may have contributed to the low bleeding 
rates we observed.
Our findings indicate that treatment with 
enoxaparin throughout the index hospitalization 
for ST-elevation myocardial infarction is superior 
to the current strategy of infusing unfractionated 
heparin for 48 hours as adjunctive antithrombin 
therapy to fibrinolysis. For every 1000 patients 
treated with the enoxaparin strategy, there would 
be 15 fewer nonfatal reinfarctions, 7 fewer epi-
sodes of urgent revascularization, and 6 fewer 
deaths, at the cost of 4 additional episodes of non-
fatal major bleeding (with no increase in the num-
ber of nonfatal intracranial hemorrhages). It is 
our judgment that despite the increase in epi-
sodes of major bleeding, the early and sustained 
reduction in ischemic events and the balance of 
efficacy and safety, as assessed by three net-clini-
cal-benefit end points, demonstrate the advantage 
of the regimen of enoxaparin over 48 hours of 
unfractionated heparin as the adjunctive anti-
thrombin regimen to support fibrinolysis.
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Table 4. Net Clinical Benefit at 30 Days.*
Outcome
Enoxaparin
(N = 10,256)
Unfractionated 
Heparin
(N = 10,223)
Relative Risk
(95% CI) P Value
number (percent)
Death, nonfatal MI, or nonfatal dis-
abling stroke
1038 (10.1) 1260 (12.3) 0.82 (0.76–0.89) <0.001
Death, nonfatal MI, or nonfatal major 
bleeding
1128 (11.0) 1305 (12.8) 0.86 (0.80 –0.93) <0.001
Death, nonfatal MI, or nonfatal intra-
cranial hemorrhage
1040 (10.1) 1250 (12.2) 0.83 (0.77– 0.90) <0.001
* The composite end points listed were calculated in a hierarchical fashion in the order shown, and equivalent weight 
was assigned to each of the three elements. CI denotes confidence interval, and MI myocardial infarction.
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